Access to Medicines

Pfizer and BioNTech Profiteering Exposed – More than Enough is Enough 

Access to Medicines

Biden Can’t Correct Vaccine Apartheid on Big Pharma’s Terms 

Access to Medicines

Expanding Vaccine Manufacturing Capacity Solely Within the Pharma Cartel is a Recipe for Perpetual Vaccine Apa... 

Access to Medicines

New ViiV license with the Medicines Patent Pool expands access but eviscerates transparency 

Access to Medicines

South Africa and India’s Proposal to Waive Recognition and Enforcement of Intellectual Property Rights for C... 

Access to Medicines

Moderna Responds to Activist Pressure, But In the Race for Our Lives, We Need More Than Baby Steps 

Access to Medicines

In Addition to Outrageous Prices and Preferential Supply to the US only, Gilead’s Allowance for Compulsory L... 

Access to Medicines

U.S.-, China- and EU-First Nationalism and COVID-19 Technology Hoarding Push the Rest of the World to the End ... 

Access to Medicines

Gilead Remdesivir Licenses: Half Measures are Not Nearly Good Enough 

Access to Medicines

Without a Global Approach to Deadly Inequities in Access to Possible COVID-19 Treatments and Vaccines, Legisla... 

Access to Medicines

Expect a Wave of Pro-IP Proposals from Industry in the Wake of the COVID-19 

Access to Medicines

Drug Companies are Running Scared – Let’s Make Them Run Faster 

Access to Medicines

Rationale for Supporting Costa Rica’s Proposal for Emergency COVID-19 Technology IP Pool for All Countries 

Access to Medicines

Generic Licensing: the Only Path Through the Maze of Gilead and U.S. Patents that Achieves Access to Affordabl... 

Access to Medicines

House Democrats Must Include Generic Licensing Provisions in H.R. 3 in Order to Deliver a Meaningful Check on... 

SEE MORE